Notice of Results

21 March 2013

LSE: VER

Notice of Results for the Twelve Months Ended 31 December 2012

Vernalis plc today announces its year end results for the twelve months ended 31 December 2012 will be released on Wednesday, 10 April 2013. The earnings announcement will be distributed at 7:00 am (UK) and will be available to download from www.vernalis.com.

Following the results announcement, the Company will host an analyst presentation and concurrent conference call at 9:00 am (UK) on 10 April 2013. The presentation will be held at the offices of Brunswick Group, 16 Lincoln's Inn Fields, London, WC2A 3ED. Please contact Valerie Mugridge at Brunswick on +44 (0) 207 396 5325 if you plan to attend in person.

-- ends -

Enquiries:

Notes to Editors

About Vernalis

Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough/cold market as well as seven programmes in its NCE development pipeline. Vernalis has significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products are endorsed by collaborations with Endo, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.

For further information about Vernalis, please visit www.vernalis.com

Vernalis Forward-Looking Statement

This news release may contain forward-looking statements that reflect the Company's current expectations regarding future events including the clinical development and regulatory clearance of the Company's products, the Company's ability to find partners for the development and commercialisation of its products, as well as the Company's future capital raising activities. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion of clinical studies, the uncertainties related to the regulatory process, the ability of the Company to identify and agree beneficial terms with suitable partners for the commercialisation and/or development of its products, as well as the achievement of expected synergies from such transactions, the acceptance of frovatriptan and other products by consumers and medical professionals, the successful integration of completed mergers and acquisitions and achievement of expected synergies from such transactions, and the ability of the Company to identify and consummate suitable strategic and business combination transactions.